Singapore, Aug. 17 -- Shanghai Henlius Biotech has entered into a strategic collaboration with Sandoz, a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius.

The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.

In April 2025, the two companies entered into an exclusive commercialisation partnership for HLX13, Henlius' proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. This new agreement further deepens the existing oncology biosimilars collaboration between the two parties.

Unde...